| Medical and Health Sciences | Lifetime | 501 | FR 7 | 99.98 |
| Hepatology | Lifetime | 35 | FR 5 | 99.77 |
| Pulmonary and Respiratory Medicine | Lifetime | 328 | FR 16 | 99.59 |
| Rheumatology | Lifetime | 152 | FR 8 | 99.39 |
| Epidemiology | Lifetime | 522 | FR 17 | 99.35 |
| Medical Genetics | Lifetime | 344 | FR 15 | 97.12 |
| Ophthalmology | Lifetime | 510 | FR 9 | 94.88 |
| Hematology | Lifetime | 702 | FR 26 | 93.92 |
| Nephrology | Lifetime | 982 | FR 33 | 80.77 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 426 | FR 28 | 95.49 |
| Rheumatology | 2021-2025 | 323 | FR 15 | 88.30 |
| Hematology | 2021-2025 | 300 | FR 13 | 86.61 |
| Ophthalmology | 2021-2025 | 235 | FR 4 | 86.83 |
| Infectious Diseases | 2021-2025 | 978 | FR 42 | 69.37 |
| Hepatitis C virus research | Lifetime | 15 | FR 3 | 99.92 |
| Systemic Lupus Erythematosus Research | Lifetime | 15 | FR 1 | 99.85 |
| Vasculitis and related conditions | Lifetime | 11 | FR 2 | 99.79 |
| Liver Disease Diagnosis and Treatment | Lifetime | 122 | FR 13 | 99.78 |
| Hepatitis B Virus Studies | Lifetime | 107 | FR 7 | 99.61 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 14 | FR 1 | 99.38 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 215 | FR 15 | 99.35 |
| Peripheral Artery Disease Management | Lifetime | 128 | FR 2 | 98.93 |
| Liver Diseases and Immunity | Lifetime | 86 | FR 9 | 99.03 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 59 | FR 7 | 98.98 |
| Kawasaki Disease and Coronary Complications | Lifetime | 48 | FR 3 | 98.36 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 104 | FR 6 | 98.88 |
| COVID-19 Clinical Research Studies | Lifetime | 551 | FR 31 | 97.92 |
| Eosinophilic Disorders and Syndromes | Lifetime | 188 | FR 17 | 98.41 |
| Pericarditis and Cardiac Tamponade | Lifetime | 99 | FR 3 | 97.14 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 208 | FR 12 | 97.29 |
| Urticaria and Related Conditions | Lifetime | 261 | FR 18 | 97.60 |
| Erythropoietin and Anemia Treatment | Lifetime | 176 | FR 8 | 97.05 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 848 | FR 61 | 96.80 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 760 | FR 43 | 96.58 |
| Retinal and Optic Conditions | Lifetime | 504 | FR 21 | 97.30 |
| Dermatological and COVID-19 studies | Lifetime | 92 | FR 5 | 94.20 |
| Renal Diseases and Glomerulopathies | Lifetime | 786 | FR 55 | 96.63 |
| Iron Metabolism and Disorders | Lifetime | 777 | FR 39 | 96.01 |
| Pulmonary Hypertension Research and Treatments | Lifetime | 1,000 | FR 60 | 95.80 |
| Cardiovascular Issues in Pregnancy | Lifetime | 597 | FR 25 | 95.76 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 772 | FR 25 | 95.59 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 964 | FR 51 | 94.05 |
| Salivary Gland Disorders and Functions | Lifetime | 659 | FR 25 | 93.95 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 241 | FR 24 | 93.40 |
| HIV-related health complications and treatments | Lifetime | 821 | FR 50 | 94.52 |
| Drug-Induced Adverse Reactions | Lifetime | 654 | FR 51 | 92.91 |
| Myasthenia Gravis and Thymoma | Lifetime | 801 | FR 45 | 92.13 |
| Autoimmune and Inflammatory Disorders | Lifetime | 909 | FR 70 | 88.70 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 730 | FR 27 | 83.13 |
| Aortic Thrombus and Embolism | Lifetime | 458 | FR 26 | 75.25 |
| Drug-Induced Ocular Toxicity | Lifetime | 918 | FR 59 | 65.04 |
| Hypertrophic osteoarthropathy and related conditions | Lifetime | 279 | FR 21 | 56.10 |
| Vasculitis and related conditions | 2021-2025 | 48 | FR 6 | 98.01 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 185 | FR 12 | 97.08 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 120 | FR 8 | 95.05 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 65 | FR 3 | 92.84 |
| Iron Metabolism and Disorders | 2021-2025 | 312 | FR 9 | 90.68 |
| Hepatitis C virus research | 2021-2025 | 780 | FR 35 | 89.41 |
| Retinal and Optic Conditions | 2021-2025 | 610 | FR 22 | 88.95 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 800 | FR 60 | 84.51 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 588 | FR 117 | 61.20 |
| Drug-Induced Ocular Toxicity | 2021-2025 | 297 | FR 22 | 29.17 |
